Richard M Logan

List of Publications by Year in Descending Order

92 papers	3,621 citations	34 h-index	58 g-index
97 ext. papers	4,226 ext. citations	4 avg, IF	5.07 L-index

#	Paper	IF	Citations
92	Diagnostic Accuracy of Confocal Laser Endomicroscopy for the Diagnosis of Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	1
91	High-Risk Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma Among Non-Indigenous and Indigenous Populations: A Systematic Review. *Otolaryngology - Head and Neck Surgery*, **2021**, 165, 23-32	5.5	2
90	Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort. *BMJ Open*, **2021**, 11, e046928	3	2
89	A systematic review and meta-analysis of the prevalence of human papillomavirus infection in Indigenous populations - A Global Picture. *Journal of Oral Pathology and Medicine*, **2021**, 50, 843-854	3.3	1
88	Incidental pathological finding during routine orthodontic treatment: a case report. *Australasian Orthodontic Journal*, **2021**, 33, 123-128		
87	Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. *Supportive Care in Cancer*, **2020**, 28, 2485-2498	3.9	20
86	Oral toxicities of cancer treatment **2020**, 371-385		
85	MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer*, **2020**, 126, 4423-4431	6.4	82
84	Prevalence of Oral Human Papillomavirus Infection Among Australian Indigenous Adults. *JAMA Network Open*, **2020**, 3, e204951	10.4	6
83	Mucositis **2019**, 1-17		
82	Mucositis **2019**, 317-333		
81	Retrospective analysis of South Australian pediatric oral and maxillofacial pathology over a 16-year period. *Journal of Investigative and Clinical Dentistry*, **2019**, 10, e12410	2.3	2
80	The Management of Pediatric Oncology Inpatients With Oral Mucositis. *Journal of Pediatric Hematology/Oncology*, **2019**, 41, e510-e516	1.2	7
79	Histological analysis of 41 dentigerous cysts in a paediatric population. *Journal of Oral Pathology and Medicine*, **2019**, 48, 74-78	3.3	8
78	The effect of a single injection of irinotecan on the development of enamel in the Wistar rats. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 1501-1506	5.6	1
77	Mouth **2018**, 1-17		
76	Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. *International Journal of Radiation Biology*, **2018**, 94, 645-655	2.9	6

75	Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. *JMIR Research Protocols*, **2018**, 7, e10503	2	13
74	The Prevalence and Investigation of Risk Factors of Oral Mucositis in a Pediatric Oncology Inpatient Population; a Prospective Study. *Journal of Pediatric Hematology/Oncology*, **2018**, 40, 15-21	1.2	10
73	Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo. *Supportive Care in Cancer*, **2018**, 26, 3873-3882	3.9	6
72	Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity. *Supportive Care in Cancer*, **2017**, 25, 1973-1983	3.9	11
71	A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. *Supportive Care in Cancer*, **2017**, 25, 687-700	3.9	9
70	TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea. *Molecular Cancer Therapeutics*, **2016**, 15, 2767-2779	6.1	27
69	Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. *International Journal of Cancer*, **2016**, 139, 2635-2645	7.5	72
68	Development and psychometric validation of social cognitive theory scales in an oral health context. *Australian and New Zealand Journal of Public Health*, **2016**, 40, 193-5	2.3	4
67	A screening model for oral cancer using risk scores: development and validation. *Community Dentistry and Oral Epidemiology*, **2016**, 44, 76-84	2.8	11
66	Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. *Supportive Care in Cancer*, **2016**, 24, 1779-88	3.9	14
65	Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms. *Molecular Cancer Therapeutics*, **2016**, 15, 1376-86	6.1	72
64	A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options. *Experimental Biology and Medicine*, **2016**, 241, 1386-94	3.7	7
63	Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. *Supportive Care in Cancer*, **2015**, 23, 1233-6	3.9	14
62	Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). *Supportive Care in Cancer*, **2015**, 23, 2233-41	3.9	100
61	Involvement of matrix metalloproteinases (MMP-3 and MMP-9) in the pathogenesis of irinotecan-induced oral mucositis. *Journal of Oral Pathology and Medicine*, **2015**, 44, 459-67	3.3	24
60	Estimating the effect of childhood socioeconomic disadvantage on oral cancer in India using marginal structural models. *Epidemiology*, **2015**, 26, 509-17	3.1	11
59	The role of oral flora in the development of chemotherapy-induced oral mucositis. *Journal of Oral Pathology and Medicine*, **2015**, 44, 81-7	3.3	37
58	Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. *Cancer Treatment Reviews*, **2015**, 41, 122-8	14.4	31

57	Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study. *Supportive Care in Cancer*, **2014**, 22, 2119-25	3.9	12
56	TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?. *International Journal of Cancer*, **2014**, 135, 2483-92	7.5	26
55	Radiation-induced oral mucositis and periodontitis - proposal for an inter-relationship. *Oral Diseases* , **2014**, 20, e7-18	3.5	30
54	Emerging evidence on the pathobiology of mucositis. *Supportive Care in Cancer*, **2013**, 21, 3233-41	3.9	89
53	Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. *Supportive Care in Cancer*, **2013**, 21, 1843-52	3.9	80
52	Implementation of a hospital oral care protocol and recording of oral mucositis in children receiving cancer treatment : a retrospective and a prospective study. *Supportive Care in Cancer*, **2013**, 21, 1113-20	3.9	23
51	Prevention of oral mucositis in children receiving cancer therapy: a systematic review and evidence-based analysis. *Oral Oncology*, **2013**, 49, 102-7	4.4	43
50	Oral conditions and their social impact among HIV dental patients, 18 years on. *Australian Dental Journal*, **2013**, 58, 18-25	2.3	15
49	Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. *Supportive Care in Cancer*, **2013**, 21, 343-55	3.9	97
48	Porphyromonas gingivalis peptidylarginine deiminase substrate specificity. *Anaerobe*, **2013**, 23, 102-8	2.8	38
47	Animal Models of Regimen-Related Toxicities **2013**, 75-95		
46	Emerging evidence on the pathobiology of mucositis. *Supportive Care in Cancer*, **2013**, 21, 2075-83	3.9	91
45	Matrix metalloproteinases: do they play a role in mucosal pathology of the oral cavity?. *Oral Diseases*, **2013**, 19, 347-59	3.5	16
44	Mammalian target of rapamycin inhibitor-associated stomatitis. *Future Oncology*, **2013**, 9, 1883-92	3.6	61
43	Epidemiology of oral cancer in Asia in the past decade--an update (2000-2012). *Asian Pacific Journal of Cancer Prevention*, **2013**, 14, 5567-77	1.7	267
42	Oral health in Australian HIV patients since the advent of combination antiretroviral therapy. *Australian Dental Journal*, **2012**, 57, 470-6; quiz 518	2.3	5
41	Histological and immunohistochemical features of gingival enlargement in a patient with AML. *Odontology / the Society of the Nippon Dental University*, **2012**, 100, 254-7	3.6	4
40	Oral Lesion as the first Clinical Presentation in Sarcoidosis: A Case Report. *Oman Medical Journal*, **2012**, 27, 243-5	1.4	11

39	Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. *Oncologist*, **2012**, 17, 135-44	5.7	74
38	Selection of housekeeping genes for gene expression studies in a rat model of irinotecan-induced mucositis. *Chemotherapy*, **2011**, 57, 43-53	3.2	11
37	Self-reported oral health of a metropolitan homeless population in Australia: comparisons with population-level data. *Australian Dental Journal*, **2011**, 56, 272-7	2.3	16
36	The treatment of oral cancer: an overview for dental professionals. *Australian Dental Journal*, **2011**, 56, 244-52, 341	2.3	18
35	Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat. *International Journal of Experimental Pathology*, **2011**, 92, 357-65	2.8	27
34	Links between oral and gastrointestinal health. *Current Opinion in Supportive and Palliative Care*, **2010**, 4, 31-5	2.6	4
33	Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. *Experimental Biology and Medicine*, **2010**, 235, 1244-56	3.7	51
32	Oral manifestations of cancer treatment in children: a review of the literature. *Clinical Journal of Oncology Nursing*, **2010**, 14, 481-90	1.1	21
31	A systematic review of orofacial pain in patients receiving cancer therapy. *Supportive Care in Cancer*, **2010**, 18, 1023-31	3.9	69
30	A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea. *Supportive Care in Cancer*, **2010**, 18, 993-1006	3.9	57
29	Kinetics and regional specificity of irinotecan-induced gene expression in the gastrointestinal tract. *Toxicology*, **2010**, 269, 1-12	4.4	10
28	Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. *Radiation Oncology*, **2010**, 5, 22	4.2	89
27	The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis. *Journal of Antimicrobial Chemotherapy*, **2009**, 63 Suppl 1, i36-40	5.1	26
26	Advances in understanding of toxicities of treatment for head and neck cancer. *Oral Oncology*, **2009** , 45, 844-8	4.4	28
25	Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?. *Cancer Chemotherapy and Pharmacology*, **2009**, 63, 239-51	3.5	124
24	Irinotecan-induced mucositis is associated with changes in intestinal mucins. *Cancer Chemotherapy and Pharmacology*, **2009**, 64, 123-32	3.5	57
23	Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. *International Journal of Experimental Pathology*, **2009**, 90, 489-99	2.8	107
22	Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. *Experimental Biology and Medicine*, **2009**, 234, 430-41	3.7	151

21	Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. *Cancer Biology and Therapy*, **2008**, 7, 1139-45	4.6	120
20	Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. *Cancer Biology and Therapy*, **2008**, 7, 1919-25	4.6	114
19	Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. *Cancer Chemotherapy and Pharmacology*, **2008**, 62, 33-41	3.5	149
18	Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. *International Journal of Cancer*, **2007**, 121, 1847-56	7.5	43
17	Retrospective study of survival and treatment pattern in a cohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004. *Oral Oncology*, **2007**, 43, 150-8	4.4	33
16	Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. *Oral Oncology*, **2007**, 43, 395-401	4.4	119
15	Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats. *Cancer Biology and Therapy*, **2007**, 6, 541-7	4.6	13
14	The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. *Cancer Treatment Reviews*, **2007**, 33, 448-60	14.4	200
13	Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma. *International Journal of Oral and Maxillofacial Surgery*, **2007**, 36, 263-6	2.9	34
12	Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. *Experimental Biology and Medicine*, **2007**, 232, 96-106	3.7	38
11	Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. *The Journal of Supportive Oncology*, **2007**, 5, 259-67		39
10	Trabecular structure of the condyle of the jaw joint in young and mature sheep: a comparative histomorphometric reference. *Archives of Oral Biology*, **2006**, 51, 29-36	2.8	11
9	The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. *Oral Oncology*, **2006**, 42, 337-42	4.4	44
8	Epidemiological analysis of tongue cancer in South Australia for the 24-year period, 1977-2001. *Australian Dental Journal*, **2006**, 51, 16-22	2.3	25
7	Radiation therapy-induced mucositis: relationships between fractionated radiation, NF-kappaB, COX-1, and COX-2. *Cancer Treatment Reviews*, **2006**, 32, 645-51	14.4	35
6	Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. *Asia-Pacific Journal of Clinical Oncology*, **2006**, 2, 39-49	1.9	20
5	Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. *Supportive Care in Cancer*, **2006**, 14, 519-27	3.9	57
4	Analysis of fluoride levels retained intraorally or ingested following routine clinical applications of topical fluoride products. *Australian Dental Journal*, **2001**, 46, 24-31	2.3	13

3	A retrospective analysis of oral hairy leukoplakia in South Australia. *Australian Dental Journal*, **2001**, 46, 108-13	2.3	5
2	A pilot study to evaluate sterile and non-sterile gloves following routine dental procedures. *Healthcare Infection*, **2000**, 5, 17-23		1
1	Altered association of protein tyrosine kinases with postsynaptic densities after transient cerebral ischemia in the rat brain. *Journal of Cerebral Blood Flow and Metabolism*, **2000**, 20, 505-12	7.3	48